Darb-Esfahani, S., Denkert, C., Stenzinger, A., Salat, C., Sinn, B., Schem, C., . . . Loibl, S. (2016). Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget.
Citação norma ChicagoDarb-Esfahani, Silvia, et al. "Role of TP53 Mutations in Triple Negative and HER2-positive Breast Cancer Treated With Neoadjuvant Anthracycline/taxane-based Chemotherapy." Oncotarget 2016.
Citação norma MLADarb-Esfahani, Silvia, et al. "Role of TP53 Mutations in Triple Negative and HER2-positive Breast Cancer Treated With Neoadjuvant Anthracycline/taxane-based Chemotherapy." Oncotarget 2016.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.